[Metabolic correction of bile outflow in patients with obstructive jaundice].

UNLABELLED: The purpose of research is to study the influence of infusion therapy structure on the of metabolic disorders and biliary excretion correction in patients with obstructive jaundice. MATERIALS AND METHODS: The study was carried out in 139 patients divided into 3 groups with the same volume of infusion therapy (1600 ml/day). In 1-St group (54 patients) infusion therapy included ringer's lactate and 10% glucose solution in the ratio of 1:1. In the 2nd group (37 patients) infusion therapy was sterofundine - G-5. In the 3rd group (48 patients) in infusion therapy have included remaxol with dosage of 800 ml/day. RESULTS: The inclusion of remaxol and sterofundin in infusion therapy leads to the improvement of biliary excretion in the early postoperative period versus ringer's lactate and 10% glucose solution. Remaxol has the advantage in metabolic disorders and biliary excretion correction versus sterofundine-G-5.

[Correction of hepatic dysfunction as pre-treatment before systemic chemotherapy in patients with bile duct neoplasms].

This prospective randomized study incorporates 141 surgical department patients with hepatobiliary tumors. The 1st group patients received 800 ml/day of remaxol. The 2nd1 group patients received Ringer solution and 10% glucose at 1:1 ratio. The subgroups included: 1 subgroup-with pre-operative cholecysto- or choledochostomia and B-subgroup-without pre-operative interventions. The combined surgical and pharmaceutical correction of bile passage, bilirubinemia, cholestasis and cytolysis by remaxole leads to better hepatic dysfunction correction and allows better timing of chemotherapy in bile passage tumors.